D-Serine deuterated - Concert Pharmaceuticals

Drug Profile

D-Serine deuterated - Concert Pharmaceuticals

Alternative Names: CTP-692

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Concert Pharmaceuticals
  • Class Adjunct therapies; Amino acids; Antipsychotics; Organic deuterium compounds; Small molecules
  • Mechanism of Action NMDA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Schizophrenia

Most Recent Events

  • 02 Aug 2018 Pharmacodynamics data from a preclinical study in Schizophrenia released by Concert Pharmaceuticals
  • 02 Aug 2018 Concert Pharmaceuticals plans a pharmacokinetic phase I trial for Schizophrenia (Adjunctive treatment) by the fourth quarter of 2018
  • 02 Aug 2018 Concert Pharmaceuticals plans a phase II trial for Schizophrenia in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top